BOSTON SCIENTIFIC CORP
About BOSTON SCIENTIFIC CORP
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $20.1B
- Net income
- -$1.3B
- Total assets
- $43.7B
- Market cap
- $72.2B
- Gross margin
- 69.0%
- Operating margin
- 18.0%
- Net margin
- 14.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $20.1B
- Cost of revenue
- $6.2B
- Gross profit
- $13.9B
- Operating expenses
- $10.2B
- Operating income
- $3.6B
- Income tax
- $493.0M
- Net income
- $2.9B
- EPS (basic)
- $1.96
- EPS (diluted)
- $1.94
Balance sheet
- Total assets
- $43.7B
- Current assets
- $8.8B
- Total liabilities
- $19.2B
- Current liabilities
- $5.4B
- Shareholders’ equity
- $24.5B
Cash flow
- Operating cash flow
- $4.5B
- Investing cash flow
- -$2.6B
- Financing cash flow
- -$395.0M
- Net cash flow
- $1.5B
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $72.2B
- P/E ratio
- 25.1
- EPS (diluted)
- $1.94
- Shares outstanding
- 1.5B
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 18, 1992
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $1.3B in FY2025.
- Revenue grew 69% from FY2021 to FY2025.
- Gross margin of 69.0%, net margin 14.4%.
- Trading 55% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 25.1.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review BOSTON SCIENTIFIC CORP.
Write a review
News about BOSTON SCIENTIFIC CORP
News & sentiment via Polygon.io
